Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock Rating Upgraded by Zacks Investment Research

Share on StockTwits

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.

According to Zacks, “Swedish Orphan Biovitrum is a biotechnology company. It develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio consists of Core Products segment which offers pharmaceuticals within Inflammation area and Genetics and metabolic therapeutic area; Partner Products segment which offers pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The company operates primarily in Sweden, Denmark, Finland, Norway, United Kingdom and France. Swedish Orphan Biovitrum is based in Solna, Sweden. “

Shares of Swedish Orphan Biovitrum AB (publ) stock opened at $17.72 on Thursday. The firm has a fifty day moving average of $17.30 and a two-hundred day moving average of $17.27. Swedish Orphan Biovitrum AB has a 52 week low of $14.64 and a 52 week high of $21.20. The company has a current ratio of 0.75, a quick ratio of 0.55 and a debt-to-equity ratio of 0.39.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.

Featured Article: Nikkei 225 Index

Get a free copy of the Zacks research report on Swedish Orphan Biovitrum AB (publ) (BIOVF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Curaleaf  Coverage Initiated at Cantor Fitzgerald
Curaleaf Coverage Initiated at Cantor Fitzgerald
Swedish Orphan Biovitrum AB   Stock Rating Upgraded by Zacks Investment Research
Swedish Orphan Biovitrum AB Stock Rating Upgraded by Zacks Investment Research
CLOSE BROS GRP/ADR  Upgraded by Citigroup to “Neutral”
CLOSE BROS GRP/ADR Upgraded by Citigroup to “Neutral”
COSCO SHIPPING/ADR  Rating Lowered to Sell at ValuEngine
COSCO SHIPPING/ADR Rating Lowered to Sell at ValuEngine
CATHAY PAC AIRW/S  Downgraded by Zacks Investment Research to “Sell”
CATHAY PAC AIRW/S Downgraded by Zacks Investment Research to “Sell”
AGEAS/S  Raised to Hold at Zacks Investment Research
AGEAS/S Raised to Hold at Zacks Investment Research


© 2006-2020 Ticker Report